Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
暂无分享,去创建一个
P. Paschka | G. Martinelli | W. Fiedler | M. Kebenko | C. Récher | J. Delaunay | N. Vey | A. Walz | C. Papayannidis | E. Raffoux | T. Prebet | C. Gomez-Roca | V. Runza | M. Brewster | R. Christen | F. Michielin | E. Guarin | V. Méresse | Ann-Marie E Bröske | M. Baehner | V. Méresse | Ann-Marie E. Bröske
[1] I. Kerridge,et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.
[2] Fabian Birzele,et al. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients , 2015, Clinical Cancer Research.
[3] J. García-Moncó,et al. The challenge of drug-induced aseptic meningitis revisited. , 2014, JAMA internal medicine.
[4] Hodgkin Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .
[5] C. Croce,et al. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. , 2013, The Journal of clinical investigation.
[6] N. Vey. Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?. , 2013, Interdisciplinary topics in gerontology.
[7] C. Chomienne,et al. CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. , 2012, Leukemia research.
[8] J. Tamburini,et al. High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.
[9] Ash A. Alizadeh,et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker , 2011, Proceedings of the National Academy of Sciences.
[10] Q. Xu. The Indian blood group system , 2011, Immunohematology.
[11] Li-ping Zhou,et al. CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity. , 2010, Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al.
[12] R. Hills,et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[14] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[15] W. Hiddemann,et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Delaunay,et al. Contribution of GM-CSF and IL-8 to the CD44-induced differentiation of acute monoblastic leukemia , 2008, Leukemia.
[17] Jean C. Y. Wang. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. , 2007, Cell stem cell.
[18] I. Weissman,et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.
[19] D. Printz,et al. Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells , 2007, European journal of clinical investigation.
[20] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[21] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[22] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[23] Bob Löwenberg,et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Herrlich,et al. CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.
[26] C. Jasmin,et al. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. , 2002, Blood.
[27] W. Sewell,et al. Drug-Induced Aseptic Meningitis , 2000, Drug safety.
[28] S. Ghaffari,et al. Altered patterns of CD44 epitope expression in human chronic and acute myeloid leukemia. , 1996, Leukemia.
[29] M. Washington,et al. A Blood Group-related Polymorphism of CD44 Abolishes a Hyaluronan-binding Consensus Sequence without Preventing Hyaluronan Binding (*) , 1996, The Journal of Biological Chemistry.
[30] M. Telen,et al. Relationship of Inb Antigen to Other Antigens on In(Lu)‐related p80 1 , 1990, Vox sanguinis.